Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
Por:
Gorriz, JL, Arroyo, D, D'Marco, L, Torra, R, Tomas, P, Puchades, MJ, Panizo, N, Pantoja, J, Montomoli, M, Llisterri, JL, Pallares-Carratala, V, Valdivielso, JM
Publicada:
25 mar 2021
Resumen:
BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls.MethodsWe evaluated 2445 CKD patients (2010-2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4years.ResultsADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels <100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221-0.808, p =0.009).ConclusionADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD.
Filiaciones:
Gorriz, JL:
Univ Valencia, Univ Clin Hosp, INCLIVA, Dept Nephrol, Av Blasco Ibanez 17, Valencia 46010, Spain
Arroyo, D:
Hosp Gen Univ Gregorio Maranon, Dept Nephrol, Madrid, Spain
D'Marco, L:
Univ Valencia, Univ Clin Hosp, INCLIVA, Dept Nephrol, Av Blasco Ibanez 17, Valencia 46010, Spain
Torra, R:
Univ Autonoma Barcelona, REDinREN, Nstituto Invest Carlos III,Inst Invest Biomed St, Fundacio Puigvert,Med Dept,Nephrol Dept,Inherited, Barcelona, Spain
Tomas, P:
Univ Valencia, Univ Clin Hosp, INCLIVA, Dept Nephrol, Av Blasco Ibanez 17, Valencia 46010, Spain
Puchades, MJ:
Univ Valencia, Univ Clin Hosp, INCLIVA, Dept Nephrol, Av Blasco Ibanez 17, Valencia 46010, Spain
Panizo, N:
Univ Valencia, Univ Clin Hosp, INCLIVA, Dept Nephrol, Av Blasco Ibanez 17, Valencia 46010, Spain
Pantoja, J:
Univ Dr Peset Hosp, Dept Nephrol, Valencia, Spain
Montomoli, M:
Univ Valencia, Univ Clin Hosp, INCLIVA, Dept Nephrol, Av Blasco Ibanez 17, Valencia 46010, Spain
Llisterri, JL:
Clin Vallada, Calle San Ramon 2, Valencia 46691, Spain
Pallares-Carratala, V:
Jaume I Univ, Castellon Mutual Insurance Union, Hlth Surveillance Unit, Dept Med, Castellon de La Plana, Spain
Valdivielso, JM:
Univ Lleida, Stat Dept 2, Vasc & Renal Translat Res Grp, UDETMA,REDinREN ISCIII,IRBLleida, Lleida, Spain
Green Published, gold
|